The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer

Regulatory and Conventional CD4+ T Cells Show Differential Effects Correlating with PD-1 and B7-H1 Expression after Immunotherapy

(2014) K. L. Alderson et al.   JOURNAL OF IMMUNOLOGY

Defective MHC Class II Presentation by Dendritic Cells Limits CD4 T Cell Help for Antitumor CD8 T Cell Responses

(2014) M. Y. Gerner et al.   JOURNAL OF IMMUNOLOGY

Targeting the Effector Site with IFN-  -Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors

(2014) A. J. Currie et al.   JOURNAL OF IMMUNOLOGY

A Potent Vaccination Strategy That Circumvents Lymphodepletion for Effective Antitumor Adoptive T-cell Therapy

(2012) H.-I. Cho et al.   CANCER RESEARCH

IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase

(2012) Connie Jackaman et al.   INTERNATIONAL IMMUNOLOGY

Agonistic Antibody to CD40 Boosts the Antitumor Activity of Adoptively Transferred T Cells In Vivo

(2012) Chengwen Liu et al.   JOURNAL OF IMMUNOTHERAPY

Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy

(2011) Brandon Kwong et al.   BIOMATERIALS

Poking CD40 for cancer therapy, another example of the Goldilocks effect

(2011) Joseph J. Drabick et al.   CANCER BIOLOGY & THERAPY

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors

(2011) Jens Rüter et al.   CANCER BIOLOGY & THERAPY

Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responses

(2011) Connie Jackaman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice

(2011) Ronald P. Gladue et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody

(2011) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization

(2011) Satwinder Kaur Singh et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

(2011) A. L. White et al.   JOURNAL OF IMMUNOLOGY

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

(2011) A. J. Christiansen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

(2011) G. L. Beatty et al.   SCIENCE

Inhibitory Fc  Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

(2011) F. Li et al.   SCIENCE

CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma

(2011) B. Burington et al.   Science Translational Medicine

Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy

(2010) Christopher F. Nicodemus et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

CD8α+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor

(2010) Alison M. McDonnell et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages

(2010) Ilia N. Buhtoiarov et al.   IMMUNOLOGY

CD40-activated B cells contribute to mesothelioma tumor regression

(2010) Connie Jackaman et al.   IMMUNOLOGY AND CELL BIOLOGY

B Cells Are Required for Optimal CD4+ and CD8+ T Cell Tumor Immunity: Therapeutic B Cell Depletion Enhances B16 Melanoma Growth in Mice

(2010) D. J. DiLillo et al.   JOURNAL OF IMMUNOLOGY

Prevention of Interleukin-2 Withdrawal-Induced Apoptosis in Lymphocytes Retrovirally Cotransduced With Genes Encoding an Antitumor T-cell Receptor and an Antiapoptotic Protein

(2010) Anusha Kalbasi et al.   JOURNAL OF IMMUNOTHERAPY

Enhanced T-cell-independent Antitumor Effect of Cyclophosphamide Combined With Anti-CD40 mAb and CpG in Mice

(2010) Erik E. Johnson et al.   JOURNAL OF IMMUNOTHERAPY

Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice

(2010) Jennifer A Westwood et al.   Journal of Translational Medicine

Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell–licensed DCs

(2010) Verena Semmling et al.   NATURE IMMUNOLOGY

Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8+ T cell responses to influenza

(2010) André Ballesteros-Tato et al.   NATURE IMMUNOLOGY

Targeting Toll-like receptors: emerging therapeutics?

(2010) Elizabeth J. Hennessy et al.   NATURE REVIEWS DRUG DISCOVERY

Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model

(2010) Maria R. Sorensen et al.   VACCINE

Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens

(2009) Sang-Ki Kim et al.   ANNALS OF HEMATOLOGY

Why are tumour blood vessels abnormal and why is it important to know?

(2009) J A Nagy et al.   BRITISH JOURNAL OF CANCER

Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy

(2009) S. A. Broomfield et al.   JOURNAL OF IMMUNOLOGY

Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation

(2009) Erica L Carpenter et al.   Journal of Translational Medicine

Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells

(2009) Sammy Bedoui et al.   NATURE IMMUNOLOGY

B-Cell–Depleting Induction Therapy and Acute Cellular Rejection

(2009) Menna R. Clatworthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer

(2009) M. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment

(2009) J. M. Weiss et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses

(2009) Ana Lucia Dominguez et al.   VACCINE

Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines

(2008) C. L. Ahonen et al.   BLOOD

The novel bispecific diabody CD40CD28 strengthens leukaemic dendritic cell-induced T-cell reactivity

(2008) Ilse Houtenbos et al.   BRITISH JOURNAL OF HAEMATOLOGY

Endocytosis mechanisms and the cell biology of antigen presentation

(2008) Sven Burgdorf et al.   CURRENT OPINION IN IMMUNOLOGY

CD8– dendritic cells preferentially cross-presentSaccharomyces cerevisiae antigens

(2008) Ronald Backer et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Cancer Immunotherapy by Dendritic Cells

(2008) Cornelis J.M. Melief   IMMUNITY

Deliberately provoking local inflammation drives tumors to become their own protective vaccine site

(2008) Connie Jackaman et al.   INTERNATIONAL IMMUNOLOGY

Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice

(2008) Juliana Hamzah et al.   JOURNAL OF CLINICAL INVESTIGATION

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

(2008) A M Krieg   ONCOGENE

Is concomitant coronary artery disease an exclusion criterion for transient left ventricular apical ballooning?

(2007) Christof Burgdorf et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY